Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTR1E | P28566 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2739016 | 0.87 | — | — | |
| SCHEMBL27740616 | 0.83 | — | — | |
| SCHEMBL7593196 | 0.80 | CHRM3 (0.55) | KDM4ECHRM3 | |
| SCHEMBL27761286 | 0.79 | TSHR (0.42) | KDM4EMEN1KMT2ATSHR | |
| SCHEMBL14470862 | 0.77 | KDM4E (0.48) | KDM4ELMNAGAACHRM3MEN1 | |
| SCHEMBL2739021 | 0.77 | — | — | |
| SCHEMBL2739017 | 0.75 | — | — | |
| SCHEMBL2739019 | 0.75 | — | — | |
| SCHEMBL5665485 | 0.75 | KDM4E (0.46) | KDM4ELMNAGAACHRM3MEN1 | |
| SCHEMBL69127 | 0.72 | HTR1E (0.65) | LMNACHRM3MEN1MAPTHTR1E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088918-B2 | Noncardiotoxic pharmaceutical compounds | WILLIAMSBURG HOLDINGS LLC (US) | 2012-01-03 | — | — | US | disclosed |
| US-20060035863-A1 | Noncardiotoxic pharmaceutical compounds | B&G PARTNERS, LLC | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035863-A1 | Noncardiotoxic pharmaceutical compounds | KCNN3, TNNI3, TNNT2 | KDM4E 3018/4885LMNA 204/4885GAA 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.